Year: 2026
Type: article
Study design: Observational Study
Abstract: BACKGROUND: Cancer-related immunosuppression increases the risk of tuberculosis reactivation and worsens oncological prognosis. Tuberculosis (TB) is considered a great imitator disease, which poses a diagnostic challenge. METHODS: We retrospectively included all patients with confirmed tuberculosis admitted to Instituto Nacional de Cancerología between 2013 and 2024. Group 1 (TB group) included patients with TB only (cancer was excluded). Group 2 (TB and cancer group) included patients with confirmed cancer and TB during oncological treatment. We describe the clinical characteristics and outcomes of both groups. We report treatment toxicity and overall mortality by study group. RESULTS: We included 116 patients: 43 (37%) in Group 1 and 73 (63%) in Group 2. The median age was 45 years (IQR 33-56); 57% were men. There were more women in Group 1 (53% vs. 37% in Group 2). The most prevalent cancers were haematological malignancies. In the two groups combined, the most frequent presentation was extrapulmonary TB (43.9%), followed by pulmonary TB (32.7%) and disseminated TB (23.2%). In Group 1, the most common extrapulmonary TB was peritoneal (32.5%). In that group, 64% (7/11) of the women with peritoneal TB were initially admitted with suspected gynaecologic cancer. Hepatotoxicity was higher in Group 2 (14.5% vs. 5%, p = 0.12). Patients in Group 2 had higher odds of death than those in Group 1 (29% vs. 2.3%, OR = 17.0, 95% CI 2.19-131.34, p = 0.007). CONCLUSIONS: TB is a major cause of morbidity and mortality among patients with cancer. Female patients with abdominal TB may mimic gynaecological cancer and should be considered in the differential diagnosis of pelvic cancer. TB screening should become a routine for all cancer patients.
DOI: 10.1111/tmi.70260
Institution: Instituto Nacional de Cancerología
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W7236705187
